Watch for upcoming milestones: commercial launch of drug delivery system in H2 fiscal 2026 and potential strategic partnerships for trigeminal neuralgia/back pain programs. Continued revenue growth trajectory will be key to reducing cash burn and achieving profitability.
Price Chart
Executive Summary
NeuroOne reported fiscal Q2 2026 product revenue of $2.4M (up 72% YoY), narrowing the net loss to $2.1M ($0.25/share) from $2.3M in the prior-year quarter. The strong revenue growth, new high-net-worth investor acquiring 7.4% of shares, and regained Nasdaq compliance signal accelerating commercial adoption of the OneRF platform.
Key Financial Metrics
Key Facts
- Product revenue $2.4M, up 72% YoY from $1.4M
- Net loss of $2.1M ($0.25/share) improved from $2.3M loss ($0.44/share) in Q2 2025
- Cash and equivalents $2.8M at March 31, 2026 vs $6.6M at Sept 30, 2025
- High-net-worth investor acquired ~7.4% of outstanding stock
- Regained Nasdaq minimum bid price compliance
- Completed 16 trigeminal neuralgia cases to date; all patients reportedly pain-free
- Maintained fiscal 2026 product revenue guidance of at least $10.5M
Financial Impact
Product revenue grew 72% to $2.4M; net loss narrowed to $2.1M from $2.3M in the prior-year quarter
Risk Factors
- Cash burn continues; $2.8M cash on hand may require additional financing within 12 months
- Company is still pre-profit with net loss of $2.1M this quarter
- Dependence on market adoption of new product lines (trigeminal neuralgia, basivertebral nerve ablation)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-054744 |
| Document: ea0290094-8k_neuroone.htm | 0001213900-26-054744 |
| Document: 0001213900-26-054744-index-headers.html | 0001213900-26-054744 |
| Document: 0001213900-26-054744-index.html | 0001213900-26-054744 |
| Document: 0001213900-26-054744.txt | 0001213900-26-054744 |
| 8-K Data (Synthetic) | 0001213900-26-054744 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 22d ago | 8-K | $1.12 $1.13 | ▲ +1.35% | ▲ +0.80% | $0.8500 (−23.77%) |
Oct 5, 2026 22d ago | Press Release | $1.12 $1.13 | ▲ +1.35% | ▲ +0.80% | $0.8500 (−23.77%) |
Aug 27, 2026 8w ago | 8-K | $1.98 $1.77 | ▼ −10.61% | ▼ −10.38% | $0.8500 (−57.07%) |
Aug 13, 2026 10w ago | 8-K | $1.83 $1.94 | ▲ +6.01% | ▲ +6.21% | $0.8500 (−53.55%) |
Jun 12, 2026 19w ago | 424B5 / 8-K | $3.32 $3.25 | ▲ +2.11% | ▲ +1.51% | $0.8500 (+74.40%) |
May 22, 2026 22w ago | 8-K | $3.87 $3.73 | ▲ +3.62% | ▲ +3.63% | $0.8500 (+78.04%) |
May 12, 2026 24w ago | 8-K | $4.39 $4.51 | ▲ +2.73% | ▲ +2.16% | $0.8500 (−80.64%) |
May 4, 2026 25w ago | 8-K | $4.49 $4.43 | ▼ −1.34% | ▼ −2.13% | $0.8500 (−81.07%) |
Apr 30, 2026 25w ago | 8-K | $4.70 $4.35 | ▼ −7.45% | ▼ −7.67% | $0.8500 (−81.91%) |
Feb 25, 2026 34w ago | 8-K | $4.15 $4.02 | ▼ −3.04% | ▼ −2.59% | $0.8500 (−79.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers